KAKKIS EMIL D (President & CEO) sold 7.4% of their position (47.85K shares) of ULTRAGENYX PHARMACEUTICAL INC. on the open market
Open‑market sale worth $1.60M — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 10/23/2023ACC: 0001209191-23-053351
DirectorOfficer· President & CEO
Since Mar 2026
-47.85K
Net shares
Net seller
$1.60M
Total sold
1
Open market trades
0B · 1S
3
Total transactions
47.85K acquired · 95.71K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+47.85K
Price / share
$6.86
Trade value
$328.27K
% of position
8.0%
10/19/2023
599.18K→647.03K
Common Stock
Direct
Shares
−47.85K
Price / share
$33.52
Trade value
$1.60M
% of position
7.4%
10/19/2023
647.60K→599.74K
Total
Net shares
+0.00
Net value
-$1.28M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 10/19/2023 | M · Option Exercise | +47.85K | $6.86 | $328.27K | 8.0% | 599.18K | 647.03K |
| Common Stock Direct | 10/19/2023 | S · Sale | −47.85K | $33.52 | $1.60M | 7.4% | 647.60K | 599.74K |
| Total | +0.00 | -$1.28M | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
47.85K shares
Shares
−47.85K
Strike price
6.86
Held after
0.00
Exercisable
—
10/19/2023
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock47.85K shares | 10/19/2023 | M · Option Exercise | −47.85K | 6.86 | — | 0.00 |
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned2.26M
Total
2.26M indirect2.26M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 2.26M | Indirect |
| Total | 2.26M | 2.26M indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported